1.41
+0.03(+2.17%)
Currency In USD
| Previous Close | 1.38 |
| Open | 1.32 |
| Day High | 1.42 |
| Day Low | 1.32 |
| 52-Week High | 2.55 |
| 52-Week Low | 1.19 |
| Volume | 27,366 |
| Average Volume | 149,431 |
| Market Cap | 11.25M |
| PE | -1.12 |
| EPS | -1.26 |
| Moving Average 50 Days | 1.54 |
| Moving Average 200 Days | 1.69 |
| Change | 0.03 |
If you invested $1000 in BioRestorative Therapies, Inc. (BRTX) 10 years ago, it would be worth $0.08 as of November 11, 2025 at a share price of $1.38. Whereas If you bought $1000 worth of BioRestorative Therapies, Inc. (BRTX) shares 5 years ago, it would be worth $26.14 as of November 11, 2025 at a share price of $1.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
GlobeNewswire Inc.
Nov 05, 2025 9:30 PM GMT
MELVILLE, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it
BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market
GlobeNewswire Inc.
Oct 27, 2025 11:30 AM GMT
MELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced a major
BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio
GlobeNewswire Inc.
Oct 22, 2025 1:35 PM GMT
MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that Cr